Introduction {#Sec1}
============

Genome-wide association studies have identified an increasing number of single nucleotide polymorphisms (SNPs) associated with breast cancer risk, the majority of which have been discovered by the COGS consortium using Caucasian women of European descent \[[@CR1]\]. Whilst each SNP is only associated with small increment in risk, the indications are that a polygenic approach to genetic testing could improve estimates of individual risk, raising the possibility of individualized screening strategies for women \[[@CR2]\]. Several studies have investigated the value of combining the genomic risk estimates obtained from SNP genotyping with conventional breast cancer risk prediction algorithms such as the breast cancer risk assessment tool (BCRAT, also known as the Gail Model) and IBIS (also known as the Tyrer-Cuzick Model). The combination of SNP panels with these algorithms has been shown to improve risk prediction, reclassifying some women across risk categories and potentially changing clinical management \[[@CR3]--[@CR7]\].

Although originally developed using population data for white women, the BCRAT has been modified for Hispanic women using SEER data \[[@CR8]\] and for African American women as the modified CARE Model \[[@CR9], [@CR10]\]. Whilst the IBIS Model has only been validated for European populations, it is widely used across ethnicities in breast cancer centers throughout the USA \[[@CR11]\]. This new study investigates whether a panel of SNPs can improve breast cancer risk estimates obtained from BCRAT or IBIS for African American and Hispanic women, in terms of calibration and discriminatory accuracy. These women comprise increasing proportions of the US population and represent a large proportion of the world's population.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

We studied 7539 self-reported African American women and 3363 self-reported Hispanic women identified from within the Women's Health Initiative (WHI) SNP Health Association Resource (SHARe). Written informed consent was obtained from each participant and the study was approved by the Fred Hutchinson Cancer Research Center Institutional Review Board. Participants in the WHI had an opportunity to opt in or out of any collaborations involving commercial entities because some women may prefer not to participate in research involving commercial (as opposed to non-profit) entities. We restricted our analyses to the subset of these individuals that had consented for collaborations involving commercial entities. The interventions used in the WHI clinical trial are independent of baseline genetic and clinical risk factors by study design \[[@CR12]\], so analyses presented here were not stratified by trial intervention.

Selection of SNPs {#Sec4}
-----------------

The SNP panels used were derived from SNPs identified as being associated with breast cancer risk from studies of Caucasian women \[[@CR13]\] and for which imputed genotypes were available in WHI SHARe. This resulted in a panel of 75 SNPs for African Americans and 71 for Hispanics.

Risk prediction models {#Sec5}
----------------------

We used the BCRAT (incorporating the modified CARE model) \[[@CR9], [@CR10]\] and IBIS \[[@CR14]\] to estimate the 5-year absolute risk of breast cancer. For BCRAT, we did not have information on biopsy histopathology (i.e., presence of atypical hyperplasia) so this was coded as "unknown". Similarly for IBIS, missing family history variables were coded as "unknown".

SNP risk score and combined model risk scores {#Sec6}
---------------------------------------------

Using the approach of Mealiffe et al. \[[@CR3]\], we calculated a SNP risk score using previously published estimates of the odds ratio (OR) per allele and risk allele frequencies (*p*) \[[@CR13], [@CR15]--[@CR18]\] assuming independence of additive risks on the log OR scale. For each SNP, we calculated the unscaled population average risk as *μ* = (1 − *p*)^2^ + 2*p*(1 − *p*)OR + *p*^2^OR^2^. Adjusted risk values (with a population average risk equal to 1) were calculated as 1/*μ*, OR/*μ*, and OR^2^/*μ* for the three genotypes defined by the number of risk alleles. The overall SNP risk score was then calculated by multiplying the adjusted risk values for each of the SNPs \[[@CR5]\].

For both BCRAT and IBIS, we calculated a combined risk score by multiplying the SNP-based score by the model's predicted 5-year risk of breast cancer.

Statistical analysis {#Sec7}
--------------------

The model risk scores, SNP-based score and combined risk scores were log transformed for all analyses, and then adjusted for age using multiple linear regression. We used Pearson correlation to test for associations between the model risk scores, the SNP-based score and the combined risk scores. We then used logistic regression to estimate risk associations, in terms of OR per age-adjusted log 5-year predicted risk, while adjusting for age group. Model calibration was assessed using the Hosmer--Lemeshow goodness-of-fit test, which compares the expected and observed numbers of cases and controls within groups that were defined by deciles of risk for controls. Discrimination between cases and controls was measured using the AUCs of the risk scores.

As in Mealiffe et al. \[[@CR3]\], we categorized 5-year absolute risks as low risk (\<1.5 %), intermediate risk (≥1.5 and \<2.0 %) and high risk (≥2.0 %) and constructed reclassification tables for each of the risk prediction models as a cross-tabulation of the classification of the risk score from the original model with the risk score from the combined model. The net reclassification improvement statistic was calculated as *P*(up\|case) − *P*(down\|case) + *P*(down\|control) − *P*(up\|control), where up refers to moving to a higher risk category and down refers to moving to a lower risk category. We tested the null hypothesis that the net reclassification improvement is equal to 0 using an asymptotic *Z*-test.

Stata Release 13 \[[@CR19]\] was used for all statistical analyses; all statistical tests were two sided, and P values less than 0.05 were considered nominally statistically significant.

Results {#Sec8}
=======

African American women {#Sec9}
----------------------

The characteristics of the study participants are provided in supplementary Table [1](#Tab1){ref-type="table"}. For cases, the mean 5-year risk of breast cancer was 1.7 % (SD 0.06 %) from BCRAT and 1.3 % (SD 0.04 %) from IBIS. For controls, the mean 5-year risk of breast cancer was 1.6 % (SD 0.05 %) from BCRAT and 1.3 % (SD 0.04 %) from IBIS. The mean SNP-based score was 1.29 (SD 0.51) for cases and 1.19 (SD 0.43) for controls. Supplementary Table 2 shows the genotype distributions and the minor allele frequencies for cases and controls for each of the 75 SNPs as well as their OR per allele and the corresponding published ORs.Table 1Age-adjusted association between log-transformed risk scores and breast cancer represented as the OR per SD of the age-adjusted log-transformed risk score for African AmericansLog-transformed risk scoreOR per SD(95 % CI)*P*BCRAT1.28(1.18, 1.39)\<0.001IBIS1.04(0.94, 1.15)0.4SNP1.24(1.12, 1.37)\<0.001BCRAT × SNP1.39(1.26, 1.52)\<0.001IBIS × SNP1.22(1.10, 1.34)\<0.001Hosmer--Lemeshow goodness-of-fit test (of the age-adjusted association between log-transformed risk scores and breast cancer) using ten groups (8 degrees of freedom)BCRAT *χ* ^2^ = 21.8, *P* = 0.005IBIS *χ* ^2^ = 5.6, *P* = 0.7SNP *χ* ^2^ = 6.0, *P* = 0.6BCRAT × SNP *χ* ^2^ = 9.9, *P* = 0.3IBIS × SNP *χ* ^2^ = 6.9, *P* = 0.5

Table [1](#Tab1){ref-type="table"} shows the age group-adjusted association between the age-adjusted log-transformed risk scores and breast cancer. For each of the models, the OR per SD of the age-adjusted risk scores was higher for the combined score than for both the SNP-based score and the corresponding model risk score. The increase in OR by the addition of SNPs was 9.6 % for BCRAT and 17.5 % for IBIS.

Receiver operating characteristic curve analysis confirmed that, for each model, the combined risk score gave greater discrimination than the SNP-based score and the corresponding model risk score (Table [2](#Tab2){ref-type="table"}). The increase in AUC compared with 0.5 by the addition of SNPs was 5.4 % for BCRAT and 7.8 % for IBIS.Table 2AUC for the age-adjusted log-transformed risk scores---ASRisk scoreAUC(95 % CI)BCRAT0.56(0.53, 0.59)IBIS0.51(0.48, 0.54)SNP0.55(0.53, 0.58)BCRAT × SNP0.59(0.56, 0.61)IBIS × SNP0.55(0.52, 0.58)Change in AUC (1 degree of freedom)BCRAT *χ* ^2^ = 2.82, *P* = 0.09IBIS *χ* ^2^ = 8.69, *P* = 0.003

For each of the models, the risk scores and the combined risk scores were classified as low risk (1.5 %), intermediate risk (≥1.5 and \<2.0 %), and high risk (≥2.0 %), as shown in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. The proportion of cases moving into a higher risk category was 42.5 % for BCRAT and 37.7 % for IBIS, while the proportion of cases moving into a lower risk category was 10.1 % for BCRAT, and 6.5 % for IBIS. The proportion of controls moving into a lower risk category was 11.2 % for BCRAT, and 8.2 % for IBIS, while the proportion of controls moving into a higher risk category was 40.3 % for BCRAT and 33.5 % for IBIS. The net reclassification improvement was 0.033 for BCRAT (95 % CI −0.025, 0.089), and 0.060 for IBIS (95 % CI 0.005, 0.113).Table 3Reclassification table for SNP × Gail risk versus Gail risk in African American womenGail 5-year riskSNP risk × Gail 5-year risk\<1.5 %1.5--2.0 %\>2.0 %Total\<1.5 % Women217811157574050 Cases944160195 Controls208410746973855 Proportion of cases0.0430.0370.0790.0481.5--2.0 % Women68377911302592 Cases354176152 Controls64873810542440 Proportion of cases0.0510.0530.0670.059\>2.0 % Women4599635779 Cases166269 Controls4493573710 Proportion of cases0.0220.0610.0980.089Total Women2906199325227421 Cases13088198416 Controls2776190523247005 Proportion of cases0.0450.0440.0790.056NRI 0.033 (95 % CI −0.025, 0.089)*Z* = 0.03, *P* = 1.0Table 4Reclassification table for SNP × IBIS risk versus IBIS risk in African American womenIBIS 5-year riskSNP risk × IBIS 5-year risk\<1.5 %1.5--2.0 %\>2.0 %Total\<1.5 % Women350310886055196 Cases1855452291 Controls331810345534905 Proportion of cases0.0530.0500.0860.0561.5--2.0 % Women4694918081768 Cases19265196 Controls4504657571672 Proportion of cases0.0410.0530.0630.054\>2.0 % Women5282323457 Cases442129 Controls4878302428 Proportion of cases0.0770.0490.0650.063Total Women4024166117367421 Cases20884124416 Controls3816157716127005 Proportion of cases0.0520.0510.0710.056NRI 0.060 (95 % CI 0.005, 0.113)*Z* = 0.06, *P* = 0.9

Hispanic women {#Sec10}
--------------

The characteristics of the study participants are provided in Supplementary Table [3](#Tab3){ref-type="table"}. For cases, the mean 5-year risk of breast cancer was 1.2 % (SD 0.07 %) from BCRAT and 1.4 % (SD 0.04 %) from IBIS. For controls, the mean 5-year risk of breast cancer was 1.1 % (SD 0.06 %) from BCRAT and 1.4 % (SD 0.04 %) from IBIS. The mean SNP-based score was 1.19 (SD 0.65) for cases and 1.00 (SD 0.57) for controls. Supplementary Table [4](#Tab4){ref-type="table"} shows the genotype distributions and the minor allele frequencies for cases and controls for each of the 71 SNPs as well as their OR per allele and the corresponding published ORs.

Table [5](#Tab5){ref-type="table"} shows the age group-adjusted association between the age-adjusted log-transformed risk scores and breast cancer. For each of the models, the OR per SD of the age-adjusted risk scores was higher for the combined risk score than that for the SNP-based score and the corresponding model risk score. The increase in OR by the addition of SNPs was 19.0 % for BCRAT and 26.1 % for IBIS.Table 5Age-adjusted association between log-transformed risk scores and breast cancer represented as the OR per SD of the age-adjusted log-transformed risk score for HispanicsLog-transformed risk scoreOR per SD(95 % CI)*P*BCRAT1.25(1.08, 1.44)\<0.001IBIS1.15(0.97, 1.36)0.1SNP1.39(1.18, 1.64)\<0.001BCRAT × SNP1.48(1.26, 1.73)\<0.001IBIS × SNP1.42(1.21, 1.68)\<0.001Hosmer--Lemeshow goodness-of-fit test (of the association between log-transformed risk scores and breast cancer) using ten groups (8 degrees of freedom)BCRAT *χ* ^2^ = 5.1, *P* = 0.7IBIS *χ* ^2^ = 5.5, *P* = 0.7SNP *χ* ^2^ = 20.8, *P* = 0.01BCRAT × SNP *χ* ^2^ = 4.7, *P* = 0.8IBIS × SNP *χ* ^2^ = 3.9, *P* = 0.9

Receiver operating characteristic curve analysis confirmed that, for each model, the combined risk score gave greater discrimination than the SNP-based score and the corresponding model risk score (Table [6](#Tab6){ref-type="table"}). The increase in AUC compared with 0.5 by the addition of SNPs was 10.9 % for BCRAT and 11.3 % for IBIS.Table 6AUC for the age-adjusted log-transformed risk scoresRisk scoreAUC(95 % CI)BCRAT0.55(0.51, 0.60)IBIS0.53(0.48, 0.57)SNP0.59(0.54, 0.64)BCRAT × SNP0.61(0.56, 0.66)IBIS × SNP0.59(0.54, 0.64)Change in AUC (1 degree of freedom)BCRAT *χ* ^2^ = 5.26, *P* = 0.02IBIS *χ* ^2^ = 7.23, *P* = 0.007

For each of the models, the risk scores and the combined risk scores were classified as low risk (1.5 %), intermediate risk (≥1.5 and \<2.0 %), and high risk (≥2.0 %), as shown in Tables [7](#Tab7){ref-type="table"} and [8](#Tab8){ref-type="table"}. The proportion of cases moving into a higher risk category was 20.4 % for BCRAT and 35.4 % for IBIS, while the proportion of cases moving into a lower risk category was 6.8 % for BCRAT, and 10.8 % for IBIS. The proportion of controls moving into a lower risk category was 6.2 % for BCRAT, and 16.8 % for IBIS, while the proportion of controls moving into a higher risk category was 11.7 % for BCRAT and 23.1 % for IBIS. The net reclassification improvement was 0.082 for BCRAT (95 % CI 0.003, 0.162), and 0.181 for IBIS (95 % CI 0.085, 0.273).Table 7Reclassification table for SNP × Gail risk versus Gail risk in Hispanic womenGail 5-year riskSNP risk × Gail 5-year risk\<1.5 %1.5--2.0 %\>2.0 %Total\<1.5 % Women25641921462902 Cases98911118 Controls24661831352784 Proportion of cases0.0380.0470.0750.0411.5--2.0 % Women1284865241 Cases511016 Controls1234755225 Proportion of cases0.0390.0210.1540.066\>2.0 % Women4933123205 Cases14813 Controls4829115192 Proportion of cases0.0200.1210.0650.063Total Women27412733343348 Cases1041429147 Controls26372593053201 Proportion of cases0.0380.0510.0870.044Table 8Reclassification table for SNP × IBIS risk versus IBIS risk in Hispanic womenIBIS 5-year riskSNP risk × IBIS 5-year risk\<1.5 %1.5--2.0 %\>2.0 %Total\<1.5 % Women17413042422287 Cases67151698 Controls16742892262189 Proportion of cases0.0380.0490.0660.0431.5--2.0 % Women428160246834 Cases1072138 Controls418153225796 Proportion of cases0.0230.0440.0850.046\>2.0 % Women7352102227 Cases42511 Controls695097216 Proportion of cases0.0550.0380.0490.048Total Women22425165903348 Cases812442147 Controls21614925483201 Proportion of cases0.0360.0460.0710.044

Discussion {#Sec11}
==========

The ability of a 77-SNP panel to improve the risk estimates provided by the major breast cancer risk assessment algorithms for Caucasians (BOADICEA, BRCAPRO, BCRAT) has been previously quantified \[[@CR20]\] and the combined SNP and model risk scores are now among the strongest known measures for differentiating women with and without breast cancer, at least for Caucasian women \[[@CR20], [@CR21]\]. For example, the OR per SD of age-adjusted risk scores for the model that included the SNP score versus the same model alone was from 1.67 to 1.80 for BCRAT, and from 1.30 to 1.52 for IBIS.

The present study quantifies how much the addition of a SNP risk component can also improve the discrimination of the BCRAT and IBIS models for both African American women and Hispanic women. Specifically, for African American women the OR per SD increased from 1.25 to 1.37 when using BCRAT and from 1.04 to 1.22 when using IBIS. For Hispanic women, the corresponding changes were from 1.25 to 1.48 and from 1.15 to 1.42.

For each of the risk prediction models, the combined risk score resulted in approximately 40 % of African American cases moving into a higher risk category and approximately 10 % of controls moving into a lower risk category. For Hispanics, over 20 % of cases moved into a higher risk category, and 6 % of controls moved into a lower risk category when using BCRAT and 17 % when using IBIS. These values are higher than the two previous studies of Caucasian cohorts which identified between 3 and 10 % of cases moving to a higher risk category \[[@CR6], [@CR20]\].

The AUC value for BCRAT obtained for Hispanic women is lower than that previously reported \[[@CR8]\]. Whilst the IBIS model is widely used across ethnicities in the US it has only been validated for Caucasian populations \[[@CR22]\], and both the ORs and AUC derived here for the model alone are low for both African American and Hispanic women. For the present analysis, information was not available for second-degree relatives or for family history of ovarian cancer and it is not immediately clear whether this has impacted on the IBIS model performance. In addition to ethnicity differences and reduced pedigree inputs, the low values may reflect that IBIS was developed using data from studies of predominately postmenopausal women and is intended for use with high-risk populations \[[@CR11]\].

Similarly, the SNPs used in this study were predominantly identified by discovery GWAS of Caucasian women \[[@CR13]\]. The estimated OR per SD for the log SNP-based score alone was 1.24 for African American and 1.39 for Hispanic women, which are both lower than the estimate of 1.55 reported by Mavaddat et al. for Caucasian women \[[@CR13]\] Whilst susceptibility loci are likely to be similar across ethnicities, the informative SNPs for those loci could vary across, and remain to be confirmed, across ethnicities. Thus, the SNP risk scores used here are likely to improve once GWAS datasets use Phase I datasets of the relevant ethnic populations, and fine mapping studies have been conducted across populations.

Overall, breast cancer prevention strategies rely upon accurate risk assessment, the models for which have typically only been validated for Caucasian women. Although most national screening programs rely solely upon age as the factor to determine eligibility (e.g., inviting only women above a certain age-threshold for screening), more targeted screening based upon a calibrated risk assessment is being considered \[[@CR23]\]. We hope that the information presented in studies such as this can eventually be used to help make screening more effective, and across all populations of the world, particularly those with less resources.
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